Bayer's $7.25 Billion Hedge Ahead of Supreme Court Showdown

Bayer deploys a $7.25B settlement as a financial backstop ahead of a pivotal U.S. Supreme Court hearing on Roundup liability, while navigating a significant cash crunch.

The German pharmaceutical and life sciences giant Bayer is navigating a critical fortnight, deploying a massive financial settlement as a shield against a potentially adverse ruling from the U.S. Supreme Court. With oral arguments scheduled for April 27 in the landmark Durnell v. Monsanto case, the company has secured preliminary approval for a $7.25 billion settlement in a separate Missouri court to cap its sprawling Roundup litigation liabilities.

This dual-track legal strategy arrives as the company faces a significant cash crunch. Despite defending its core earnings forecast, Bayer anticipates a negative free cash flow for 2026, estimated at approximately 5 billion euros, due to payouts from ongoing legal disputes. This follows a steep decline in 2025, where free cash flow fell by nearly a third to 2.1 billion euros.

The Supreme Court hearing represents a pivotal moment. Bayer’s argument hinges on the principle of federal preemption, contending that the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA) overrides state-level warning label laws, since the EPA has not mandated a cancer warning for glyphosate. A favorable ruling could effectively halt new lawsuits. The court took the case due to a split in lower courts: two appellate courts rejected Bayer’s position, while the Third Circuit Court of Appeals sided with the company.

Political divisions are stark. The current U.S. administration has formally backed Bayer’s legal stance. However, attorneys general from 18 Republican-led states, including Texas, Florida, and Ohio, have filed amicus briefs opposing the company, defending their states' regulatory authority. Conversely, states like Kentucky, North Dakota, and Georgia have passed laws shielding the company from cancer-warning lawsuits.

The parallel $7.25 billion settlement in King v. Monsanto, preliminarily approved by Judge Timothy J. Boyer in March, is designed to resolve current and future non-Hodgkin lymphoma claims. Claimants have until June 4 to opt out of the agreement. This mechanism acts as a financial backstop, ensuring compensation for plaintiffs even if Bayer wins at the Supreme Court, while protecting the company from a cost explosion should the ruling go against it.

Operationally, Bayer’s business shows resilience. The company has reaffirmed its 2026 EBITDA forecast before special items, targeting 9.6 to 10.1 billion euros, compared to 9.669 billion euros in 2025. Recent U.S. import tariffs on pharmaceuticals are not seen as a threat to this guidance, as existing EU-US trade agreements cap such duties at 15 percent. The heart drug Kerendia, which saw sales surge 79 percent to 829 million euros in 2025, recently received an expanded EU approval, bolstering the pharmaceuticals division.

Shareholders will gather for the Annual General Meeting on April 24, voting on a dividend of 0.11 euros per share and the election of two new supervisory board members. Yet, all eyes will be on Washington days later. The Supreme Court’s binding ruling, expected by the end of June, will finally define the scale of the company’s future liabilities. Management has pointed to 2027 as a potential turning point for financial recovery, a prospect that hinges overwhelmingly on the justices' decision.